vs
Lineage Cell Therapeutics, Inc.（LCTX）与Rocky Mountain Chocolate Factory, Inc.（RMCF）财务数据对比。点击上方公司名可切换其他公司
Rocky Mountain Chocolate Factory, Inc.的季度营收约是Lineage Cell Therapeutics, Inc.的1.1倍（$7.5M vs $6.6M），Lineage Cell Therapeutics, Inc.净利率更高（12.9% vs -2.1%，领先14.9%），Lineage Cell Therapeutics, Inc.同比增速更快（130.4% vs -4.4%），Rocky Mountain Chocolate Factory, Inc.自由现金流更多（$-1.3M vs $-5.3M），过去两年Lineage Cell Therapeutics, Inc.的营收复合增速更高（113.9% vs 1.9%）
谱系细胞治疗公司是一家处于临床阶段的生物科技企业，专注于开发满足未竟医疗需求的新型细胞疗法。其研发项目依托自主成熟的细胞疗法专有平台，以及内部配套的研发与生产能力，可利用多能细胞和祖细胞原料，开发制造专业化的终末分化人类细胞，推进对应疗法落地。
落基山巧克力厂是美国知名巧克力企业，同时开展国际特许经营业务，集糖果生产与零售运营于一体，总部位于美国科罗拉多州杜兰戈，除美国本土门店外，在巴拿马、菲律宾也设有经营网点。
LCTX vs RMCF — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $6.6M | $7.5M |
| 净利润 | $851.0K | $-155.0K |
| 毛利率 | — | 34.0% |
| 营业利润率 | -99.1% | 1.1% |
| 净利率 | 12.9% | -2.1% |
| 营收同比 | 130.4% | -4.4% |
| 净利润同比 | 126.0% | 81.7% |
| 每股收益（稀释后） | $0.00 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $6.6M | $7.5M | ||
| Q3 25 | $3.7M | $6.8M | ||
| Q2 25 | $2.8M | $6.4M | ||
| Q1 25 | $1.5M | $8.9M | ||
| Q4 24 | $2.9M | $7.9M | ||
| Q3 24 | $3.8M | $6.4M | ||
| Q2 24 | $1.4M | $6.4M | ||
| Q1 24 | $1.4M | $7.3M |
| Q4 25 | $851.0K | $-155.0K | ||
| Q3 25 | $-29.8M | $-662.0K | ||
| Q2 25 | $-30.5M | $-324.0K | ||
| Q1 25 | $-4.1M | $-2.9M | ||
| Q4 24 | $-3.3M | $-847.0K | ||
| Q3 24 | $-3.0M | $-722.0K | ||
| Q2 24 | $-5.8M | $-1.7M | ||
| Q1 24 | $-6.5M | $-1.6M |
| Q4 25 | — | 34.0% | ||
| Q3 25 | — | 23.6% | ||
| Q2 25 | — | 31.1% | ||
| Q1 25 | 97.6% | 10.8% | ||
| Q4 24 | 94.6% | 23.4% | ||
| Q3 24 | 99.0% | 31.8% | ||
| Q2 24 | 96.9% | 12.8% | ||
| Q1 24 | 93.2% | 24.3% |
| Q4 25 | -99.1% | 1.1% | ||
| Q3 25 | -102.9% | -7.0% | ||
| Q2 25 | -715.4% | -2.3% | ||
| Q1 25 | -433.1% | -30.3% | ||
| Q4 24 | -178.2% | -8.9% | ||
| Q3 24 | -101.6% | -14.3% | ||
| Q2 24 | -416.7% | -25.4% | ||
| Q1 24 | -461.3% | -21.7% |
| Q4 25 | 12.9% | -2.1% | ||
| Q3 25 | -809.0% | -9.7% | ||
| Q2 25 | -1101.8% | -5.1% | ||
| Q1 25 | -275.6% | -32.5% | ||
| Q4 24 | -114.1% | -10.7% | ||
| Q3 24 | -80.3% | -11.3% | ||
| Q2 24 | -409.1% | -25.9% | ||
| Q1 24 | -453.0% | -21.9% |
| Q4 25 | $0.00 | $-0.02 | ||
| Q3 25 | $-0.13 | $-0.09 | ||
| Q2 25 | $-0.13 | $-0.04 | ||
| Q1 25 | $-0.02 | $-0.38 | ||
| Q4 24 | $0.00 | $-0.11 | ||
| Q3 24 | $-0.02 | $-0.11 | ||
| Q2 24 | $-0.03 | $-0.26 | ||
| Q1 24 | $-0.04 | $-0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $55.8M | $641.0K |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $44.5M | $6.0M |
| 总资产 | $112.6M | $20.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $55.8M | $641.0K | ||
| Q3 25 | $40.5M | $2.0M | ||
| Q2 25 | $42.3M | $893.0K | ||
| Q1 25 | $47.9M | $720.0K | ||
| Q4 24 | $47.8M | $1.1M | ||
| Q3 24 | $32.7M | $973.0K | ||
| Q2 24 | $38.5M | $637.0K | ||
| Q1 24 | $43.6M | $2.1M |
| Q4 25 | $44.5M | $6.0M | ||
| Q3 25 | $22.0M | $6.1M | ||
| Q2 25 | $48.4M | $6.7M | ||
| Q1 25 | $79.0M | $7.0M | ||
| Q4 24 | $78.4M | $9.8M | ||
| Q3 24 | $66.2M | $10.5M | ||
| Q2 24 | $68.3M | $9.0M | ||
| Q1 24 | $72.4M | $10.6M |
| Q4 25 | $112.6M | $20.7M | ||
| Q3 25 | $89.6M | $22.3M | ||
| Q2 25 | $90.8M | $20.1M | ||
| Q1 25 | $111.8M | $21.2M | ||
| Q4 24 | $113.2M | $21.6M | ||
| Q3 24 | $96.6M | $21.1M | ||
| Q2 24 | $102.8M | $19.0M | ||
| Q1 24 | $108.5M | $20.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.9M | $-1.2M |
| 自由现金流经营现金流 - 资本支出 | $-5.3M | $-1.3M |
| 自由现金流率自由现金流/营收 | -79.9% | -16.9% |
| 资本支出强度资本支出/营收 | 6.0% | 0.5% |
| 现金转化率经营现金流/净利润 | -5.73× | — |
| 过去12个月自由现金流最近4个季度 | $-19.4M | — |
8季度趋势，按日历期对齐
| Q4 25 | $-4.9M | $-1.2M | ||
| Q3 25 | $-3.6M | $-488.0K | ||
| Q2 25 | $-5.5M | $350.0K | ||
| Q1 25 | $-4.9M | $1.2M | ||
| Q4 24 | $-6.3M | $-2.1M | ||
| Q3 24 | $-5.8M | $-3.5M | ||
| Q2 24 | $-5.2M | $-2.2M | ||
| Q1 24 | $-5.8M | $129.0K |
| Q4 25 | $-5.3M | $-1.3M | ||
| Q3 25 | $-3.6M | $-544.0K | ||
| Q2 25 | $-5.6M | $182.0K | ||
| Q1 25 | $-5.0M | — | ||
| Q4 24 | $-6.7M | — | ||
| Q3 24 | $-5.9M | $-4.6M | ||
| Q2 24 | $-5.2M | $-2.6M | ||
| Q1 24 | $-5.8M | $-352.3K |
| Q4 25 | -79.9% | -16.9% | ||
| Q3 25 | -98.6% | -8.0% | ||
| Q2 25 | -200.8% | 2.9% | ||
| Q1 25 | -331.8% | — | ||
| Q4 24 | -234.0% | — | ||
| Q3 24 | -156.1% | -72.6% | ||
| Q2 24 | -371.2% | -40.2% | ||
| Q1 24 | -403.1% | -4.9% |
| Q4 25 | 6.0% | 0.5% | ||
| Q3 25 | 0.3% | 0.8% | ||
| Q2 25 | 0.5% | 2.6% | ||
| Q1 25 | 6.5% | — | ||
| Q4 24 | 12.7% | — | ||
| Q3 24 | 3.0% | 17.5% | ||
| Q2 24 | 3.6% | 6.5% | ||
| Q1 24 | 2.6% | 6.6% |
| Q4 25 | -5.73× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LCTX
| Collaboration Revenues | $6.3M | 95% |
| Other | $345.0K | 5% |
RMCF
| Manufacturing | $5.9M | 78% |
| Transferred At Point In Time | $1.2M | 16% |
| Other | $414.0K | 5% |
